Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163
Background and Aims: Macrophages play an important role in the development of nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH). In this study, we investigated the hepatic expression of the macrophage scavenger receptor CD163 and the plasma level of...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Gastro Hep Advances |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772572323000419 |
| _version_ | 1797777418691280896 |
|---|---|
| author | Maria Kløjgaard Skytthe Felix Boel Pedersen Charlotte Wilhelmina Wernberg Vineesh Indira Chandran Aleksander Krag Tina Di Caterino Samuel Coelho Mandacaru Blagoy Blagoev Mette Munk Lauridsen Sönke Detlefsen Jonas Heilskov Graversen Søren Kragh Moestrup |
| author_facet | Maria Kløjgaard Skytthe Felix Boel Pedersen Charlotte Wilhelmina Wernberg Vineesh Indira Chandran Aleksander Krag Tina Di Caterino Samuel Coelho Mandacaru Blagoy Blagoev Mette Munk Lauridsen Sönke Detlefsen Jonas Heilskov Graversen Søren Kragh Moestrup |
| author_sort | Maria Kløjgaard Skytthe |
| collection | DOAJ |
| description | Background and Aims: Macrophages play an important role in the development of nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH). In this study, we investigated the hepatic expression of the macrophage scavenger receptor CD163 and the plasma level of its shed soluble form (sCD163) in patients with obesity and NASH, non-NASH NAFLD (NAFL), or healthy livers (no NAFLD). Methods: Paired liver biopsies and plasma samples were collected from 61 patients with obesity (body mass index ≥35). Hepatic expression of CD163 was analyzed by immunohistochemistry and data-independent acquisition mass spectrometry, whilst plasma levels of sCD163 were determined by enzyme-linked immunosorbent assay and data-independent acquisition mass spectrometry. NAFLD stage and activity were assessed using the Kleiner fibrosis and NASH Clinical Research Network (NAS-CRN) scoring system. Results: sCD163 turned out as a promising predictor of NASH with an area under the receiver-operating characteristic curve of 0.78 [0.65;0.92] (P = .0008). sCD163 increased with more severe NAFLD both in univariate (odds ratio [OR] = 3.31[1.80;6.11], P < .001) and multivariable ordinal logistic regression adjusting for NAFLD risk factors (OR = 2.02 [1.03;3.97], P = .042). On the other hand, hepatic expression of CD163 was negatively associated with more severe NAFLD in univariate ordinal logistic regression determined by immunohistochemistry (OR = 0.91[0.84;0.98], P = .015) and proteomics (OR = 0.13[0.02;0.80], P = .028). Taking NAFLD risk factors into account, hepatic expression of CD163 was only associated with the fibrosis stage (OR = 0.01 [0.0003;0.21], P = .004). Accordingly, hepatic CD163 surface expression and sCD163 were negatively correlated (rho = −0.478, P = .0001). Conclusion: An increased plasma sCD163 and a concurrent decreased hepatic expression of CD163 are strongly associated with NAFLD in obese patients. |
| first_indexed | 2024-03-12T23:04:43Z |
| format | Article |
| id | doaj.art-74d5897d531b4a1f86e9c429e3094ae4 |
| institution | Directory Open Access Journal |
| issn | 2772-5723 |
| language | English |
| last_indexed | 2024-03-12T23:04:43Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gastro Hep Advances |
| spelling | doaj.art-74d5897d531b4a1f86e9c429e3094ae42023-07-19T04:24:08ZengElsevierGastro Hep Advances2772-57232023-01-0125711720Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163Maria Kløjgaard Skytthe0Felix Boel Pedersen1Charlotte Wilhelmina Wernberg2Vineesh Indira Chandran3Aleksander Krag4Tina Di Caterino5Samuel Coelho Mandacaru6Blagoy Blagoev7Mette Munk Lauridsen8Sönke Detlefsen9Jonas Heilskov Graversen10Søren Kragh Moestrup11Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Correspondence: Address correspondence to: Maria Kløjgaard Skytthe, MSc, University of Southern Denmark, J. B. Winsløwsvej 25, 5230 Odense, Denmark.Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, DenmarkDepartment of Gastroenterology and Hepatology, Liver Research Group, University Hospital of South Denmark, Esbjerg, DenmarkDepartment of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Gastroenterology and Hepatology, Liver Research Group, University Hospital of South Denmark, Esbjerg, Denmark; Department of Gastroenterology and Hepatology, Centre for Liver Research, Odense University Hospital, Odense, DenmarkDepartment of Pathology, Odense University Hospital, Odense DenmarkDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, DenmarkDepartment of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, DenmarkDepartment of Gastroenterology and Hepatology, Liver Research Group, University Hospital of South Denmark, Esbjerg, DenmarkDepartment of Pathology, Odense University Hospital, Odense Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, DenmarkDepartment of Molecular Medicine, University of Southern Denmark, Odense, DenmarkDepartment of Molecular Medicine, University of Southern Denmark, Odense, Denmark; Department of Biomedicine, Aarhus University, Aarhus Denmark; Department of Clinical Biochemistry, Aarhus University Hospital, DenmarkBackground and Aims: Macrophages play an important role in the development of nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH). In this study, we investigated the hepatic expression of the macrophage scavenger receptor CD163 and the plasma level of its shed soluble form (sCD163) in patients with obesity and NASH, non-NASH NAFLD (NAFL), or healthy livers (no NAFLD). Methods: Paired liver biopsies and plasma samples were collected from 61 patients with obesity (body mass index ≥35). Hepatic expression of CD163 was analyzed by immunohistochemistry and data-independent acquisition mass spectrometry, whilst plasma levels of sCD163 were determined by enzyme-linked immunosorbent assay and data-independent acquisition mass spectrometry. NAFLD stage and activity were assessed using the Kleiner fibrosis and NASH Clinical Research Network (NAS-CRN) scoring system. Results: sCD163 turned out as a promising predictor of NASH with an area under the receiver-operating characteristic curve of 0.78 [0.65;0.92] (P = .0008). sCD163 increased with more severe NAFLD both in univariate (odds ratio [OR] = 3.31[1.80;6.11], P < .001) and multivariable ordinal logistic regression adjusting for NAFLD risk factors (OR = 2.02 [1.03;3.97], P = .042). On the other hand, hepatic expression of CD163 was negatively associated with more severe NAFLD in univariate ordinal logistic regression determined by immunohistochemistry (OR = 0.91[0.84;0.98], P = .015) and proteomics (OR = 0.13[0.02;0.80], P = .028). Taking NAFLD risk factors into account, hepatic expression of CD163 was only associated with the fibrosis stage (OR = 0.01 [0.0003;0.21], P = .004). Accordingly, hepatic CD163 surface expression and sCD163 were negatively correlated (rho = −0.478, P = .0001). Conclusion: An increased plasma sCD163 and a concurrent decreased hepatic expression of CD163 are strongly associated with NAFLD in obese patients.http://www.sciencedirect.com/science/article/pii/S2772572323000419CD163NASHNAFLDImmunohistochemistryProteomicsTranslational |
| spellingShingle | Maria Kløjgaard Skytthe Felix Boel Pedersen Charlotte Wilhelmina Wernberg Vineesh Indira Chandran Aleksander Krag Tina Di Caterino Samuel Coelho Mandacaru Blagoy Blagoev Mette Munk Lauridsen Sönke Detlefsen Jonas Heilskov Graversen Søren Kragh Moestrup Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163 Gastro Hep Advances CD163 NASH NAFLD Immunohistochemistry Proteomics Translational |
| title | Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163 |
| title_full | Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163 |
| title_fullStr | Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163 |
| title_full_unstemmed | Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163 |
| title_short | Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163 |
| title_sort | obese patients with nonalcoholic fatty liver disease have an increase in soluble plasma cd163 and a concurrent decrease in hepatic expression of cd163 |
| topic | CD163 NASH NAFLD Immunohistochemistry Proteomics Translational |
| url | http://www.sciencedirect.com/science/article/pii/S2772572323000419 |
| work_keys_str_mv | AT mariakløjgaardskytthe obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT felixboelpedersen obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT charlottewilhelminawernberg obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT vineeshindirachandran obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT aleksanderkrag obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT tinadicaterino obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT samuelcoelhomandacaru obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT blagoyblagoev obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT mettemunklauridsen obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT sonkedetlefsen obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT jonasheilskovgraversen obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 AT sørenkraghmoestrup obesepatientswithnonalcoholicfattyliverdiseasehaveanincreaseinsolubleplasmacd163andaconcurrentdecreaseinhepaticexpressionofcd163 |